Please login to the form below
blood disorders
This page shows the latest blood disorders news and features for those working in and with pharma, biotech and healthcare.
Lab-grown red blood cells used for human transfusions in world-first clinical trial
Manufactured blood cells could revolutionise treatments for people with blood disorders. ... It is hoped the approach could ‘revolutionise’ treatments for people with blood disorders such as sickle cell disease and rare blood types who require
Latest news
-
Novo Nordisk completes acquisition of Forma Therapeutics in deal worth $1.1bn
company’s blood disorders portfolio. ... an investigational oral, once-daily, selective pyruvate kinase-R (PKR) activator, being developed to improve anaemia and red blood cell health in people with sickle cell disease (SCD).
-
Pfizer completes acquisition of Global Blood Therapeutics for $5.4bn
Pfizer has announced the completion of its acquisition of Global Blood Therapeutics (GBT), a biopharma focusing on drug discovery and development of treatments for rare blood disorders including sickle cell disease ... SCD is a lifelong, incurable
-
Novo Nordisk to acquire Forma Therapeutics in deal worth $1.1bn
The acquisition will focus on expanding the company’s blood disorders portfolio. ... Novo Nordisk and Forma Therapeutics (Forma) have entered into a definitive agreement, under which Novo Nordisk will acquire Forma in a deal worth $1.1bn to expand its
-
Pfizer set to acquire Global Blood Therapeutics in deal worth $5.4bn
The acquisition will help accelerate research into sickle cell disease. Pfizer and Global Blood Therapeutics (GBT) have announced that Pfizer will acquire GBT. ... GBT focuses on drug discovery and development for rare blood disorders and Pfizer has an
-
Roche reinforces commitment to the World Federation of Hemophilia Humanitarian Aid Program
Haemophilia A is an inherited, serious disease whereby a patient’s blood is unable to clot properly, which can often cause uncontrolled and spontaneous bleeding. ... disorders. More than 22, 000 people with haemophilia in over 112 countries have
More from news
Approximately 3 fully matching, plus 51 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
In the meantime, Sanofi is stepping up its focus in other areas like immunological and inflammatory diseases, rare blood disorders and vaccines, as well as cancer – an area it had been
-
Novo Nordisk awakens its ‘Sleeping Beauty’
The company is now projecting long-term improvements across its two main areas of haemophilia and growth hormone disorders, with confidence radiating into all quarters of its business. ... disorders field because we have access to this great science and
-
The challenges of making genomics a reality for patients
This approach is now being applied to diseases such as sickle cell, a group of inherited blood disorders.
-
The challenges of making genomics a reality for patients today, not tomorrow
This approach is now being applied to diseases such as sickle cell, a group of inherited blood disorders.
-
Deal Watch January 2018
well as a pipeline of candidates focused on rare blood disorders. ... Portfolio/pipeline in haemophilia and other rare blood disorders. Acquisition company. 11, 600.
More from intelligence
Approximately 1 fully matching, plus 7 partially matching documents found.
Latest appointments
-
Kiadis Pharma appoints Vincent Brichard to supervisory board
Kiadis has a focus on research, development and commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders, including its lead product Atir. ... Atir achieved some extremely compelling clinical
-
Life keeps on growing with appointment of Kirsty Mead
blood disorders.
-
Cellerant appoints William Reed as VP clinical development
Will lead development of stem cell-based treatments for blood conditions and cancer. ... Dr Reed joins from Cerus Corporation and will lead the development of Cellerant's stem cell-based cellular and antibody therapies for blood disorders and cancer.
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Products as portfolios: positioning immuno-oncology products
The cancer landscape is changing. Immunotherapeutic advances are driving significant improvements in treatment options for sufferers of many types of cancers and blood disorders. ... Within blood cancers, PD-(L) 1s and also monoclonal antibodies, in
-
Life keeps on growing
Previously Kirsty worked on MedEd accounts at Adventis Health. During her marketing degree she also spent a year at Baxter Healthcare as a marketing executive working on rare blood disorders.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- AstraZeneca joins UK pilot evaluating AI-based lung cancer diagnosis system
- Eli Lilly’s Alzheimer’s drug denied FDA accelerated approval
- EU to revise pharmaceuticals law amid antibiotic shortages
- Medical Affairs: centre-stage in scientific engagement strategies
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Tidepool’s automated insulin dosing app for type 1 diabetes gets FDA approval
- UK to introduce new regulatory framework for point of care manufacturing
- Navigating the patient experience to improve retention of clinical trial participants
- Europe’s cancer community publishes new report on transforming patient care
- Alzheimer’s Research UK welcomes government’s pledge to tackle dementia crisis
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- EU to revise pharmaceuticals law amid antibiotic shortages
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Why everyone in pharma is bending over backwards to be agile
PMHub
Collected Group
Collected Group is a forward thinking healthcare communication company that supports biopharma and diagnostic companies to engage in more lasting...
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
